Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPI-2265 and Olaparib in mCRPC
NCT06909825Phase 2Active, not recruiting
- Sponsor
- Fusion Pharmaceuticals Inc.
- Start
- Feb 2025
- Primary completion
- May 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label trial of actinium-225 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Fusion Pharmaceuticals Inc. Primary endpoints: Anti-tumour activity of FPI-2265 administered in combination with olaparib at 12 weeks and Safety and tolerability of FPI-2265 administered in combination with olaparib at 5 years. Started Feb 2025; status: active, not recruiting.
02
Drugs
actinium-225 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06909825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909825.